Pioneering Cancer Therapeutics Startup, ExSURE PVT. LTD., Secures Funding for Next-Gen Drug-Delivery Platform

We are excited to announce that ExSURE PVT. LTD.

has successfully raised a significant amount of funding as we continue our mission to revolutionize cancer treatment through innovative research and development.

Specializing in exosome-based therapeutics, our startup is at the forefront of creating a groundbreaking chemotherapeutic drug-delivery platform designed to deliver anti-cancer drugs directly into tumor cells and relapse-causing cancer stem cells, all while minimizing damage to healthy cells.

This unique mechanism of action stands to dramatically reduce chemotoxicity and the risk of cancer relapse, addressing a critical need in oncology care.

Our recent funding will primarily be utilized to advance our platform from in vitro and ex-vivo validations to in vivo studies using SCID mice, an essential step in our development process.

Having already shown promising results in various breast cancer cell lines and chemo-naive clinical samples, we are eager to progress further in validating our approach.

Additionally, the funding will support our upcoming patent filing for our innovative formulation and methodologies that underpin the bioengineered drug-loaded targeted exosomes.

Beyond our core research, ExSURE also offers a range of outsourcing services, including cell-culture-based assays and cancer stem cell-based experimentation, aimed at accelerating discovery in cancer research.

As we look to the future, we are optimistic that our advancements in exosome technology can lead to more effective, personalized cancer treatment solutions.

Stay tuned for more updates as we continue our journey towards making a meaningful impact in the fight against cancer!